← Back to Search

Other

CXL for Keratoconus

Phase 3
Recruiting
Research Sponsored by Rush Eye Associates
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 10-70
Diagnosis of corneal ectasia disorder
Must not have
Unwilling or unable to participate in trial
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Summary

This trial looks at different ways of doing a corneal cross-linking treatment to see which is better for treating corneal dystrophies.

Who is the study for?
This trial is for people aged 10-70 with a corneal condition called ectasia, which includes keratoconus. Participants must be willing to join the study.
What is being tested?
The study tests corneal collagen cross-linking (CXL), a treatment for strengthening the cornea in patients with conditions like keratoconus, using different surgical techniques.
What are the potential side effects?
Possible side effects of CXL may include temporary eye pain and discomfort, blurred vision, risk of infection, and rarely, permanent changes in vision.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between the ages of 10 and 70.
Select...
I have been diagnosed with a corneal ectasia disorder.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not willing or able to participate in the trial.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Keratometry measurements
Visual acuity

Trial Design

2Treatment groups
Active Control
Group I: Epithelium onActive Control1 Intervention
Epi not removed during CXL treatment
Group II: Epithelium offActive Control1 Intervention
Epi removed before CXL treatment

Find a Location

Who is running the clinical trial?

Rush Eye AssociatesLead Sponsor
6 Previous Clinical Trials
971 Total Patients Enrolled

Media Library

CXL (Other) Clinical Trial Eligibility Overview. Trial Name: NCT01708538 — Phase 3
Keratoconus Research Study Groups: Epithelium on, Epithelium off
Keratoconus Clinical Trial 2023: CXL Highlights & Side Effects. Trial Name: NCT01708538 — Phase 3
CXL (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01708538 — Phase 3
~0 spots leftby Oct 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top